Cephalon, Inc.

89Bio, Inc.

Cancer Research Technology Limited

Venatorx Pharmaceuticals, Inc.

Pharmacopeia Inc.

Ignyta, Inc.

Teva Sante

Allison L Zulli

Robert L Hudkins

Nadine C Becknell

Ming Tao

Craig A Zificsak

Bruce D Dorsey

Reddeppa Reddy Dandu

Derek D Dunn

Eugen F Mesaros

Theodore L Underiner

Edward R Bacon

Sankar Chatterjee

Dimitar B Gotchev

Linda Weinberg

Kurt A Josef

James L Diebold

Dandu R Reddy

Thomas R Bailey

Christopher J Burns

Steven Armen Boyd

Gregory R Ott

Robert E Lee Trout

Diane E Gingrich

Benjamin J Dugan

Greg A Hostetler

Melody McWherter

Jodie Hamrick

Katherine M Fowler

Emma L Morris

Christelle N Soudy

Lars J S Knutsen

Nathaniel J T Monck

Ikeoluwa Olowoye

Gregoire A Pave

Henry Joseph Breslin

Stephen M Condon

Denis Daigle

Guo-Hua Chu

Peter D Brown

David B Whitman

Bruce A Ruggeri

Babu G Sundar

Jonathan R A Roffey

Cullen L Myers

Reddeppareddy Dandu

Tao Guo

Zhenrong Xu

Daniel C Pevear

Randy W Jackson

Chia-Yu Huang

Brigitte Lesur

Gregory J Wells

Christophe Yue

Minglang Wu

Jonathan R Roffey

Lisa Guise-Zawacki

Lawrence Rosen

Matthew Lucas

Nathaniel Jt Monck

Henry J Breslin

Robert Simpson

Jonathan RA Roffey

Greg Hosteler

Yijun Deng

Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses.

Spiropiperidine derivatives

Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

Penicillin-binding protein inhibitors

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.

1,4-substituted piperidine derivatives

Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses. 

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses. 

Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

Beta-lactamase inhibitors

The present application provides a compound of formula (I) and/or a salt thereof, wherein R, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.

Azaquinazoline inhibitors of atypical protein kinase C

The present application provides azaquinazoline compounds as defined herein. This application further describes compositions comprising the same. These azaquinazoline compounds and their salts have atypical protein kinase C ('aPKC') inhibitory activity, and may be used to treat proliferative disorders.

Azaquinazoline inhibitors of Atypical protein Kinase C

The invention is directed to pyrazolo[1,5-a]pyridine derivatives and their use as AXL and c-MET kinase inhibitors.

Pyrazolo[1,5-a]pyridine derivatives and methods of their use

The present application provides a compound of formula (I) or a salt thereof, wherein R, R, R, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.

Growing community of inventors

Wayne, PA, United States of America

Allison L Zulli